Twist Bioscience Corporation (TWST)

NMS – Real vaqt narxi. Valyuta: USD

99.84

+3.19 (3.30%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

99.52

-0.32 (-0.32%)

Bozordan keyin: Jun 26, 2026, 7:47 PM EDT

12.06.2026

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

12,000 shares were exercised from options and sold for a total of ~$673,000 on May 12, 2026. All shares were transacted directly via option exercise and immediate sale; no indirect entities or gifts were involved.

12.06.2026

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

06.06.2026

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

Dennis Cho sold 14,205 shares on May 29, 2026, for a total transaction value of ~$991,000, at a reported price of $69.75 per share. This transaction reduced Cho's direct holdings from 134,299 shares to 120,094 shares.

02.06.2026

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

27.05.2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.

26.05.2026

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

08.05.2026

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

05.05.2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.

04.05.2026

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder.

04.05.2026

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw.

Twist Bioscience Corporation (TWST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Twist Bioscience Corporation (TWST)

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Videolar

No Data

Press-relizlar

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Videolar

No Data

Press-relizlar

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Search stocks

Twist Bioscience Corporation (TWST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Twist Bioscience Corporation (TWST)

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Videolar

No Data

Press-relizlar

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Videolar

No Data

Press-relizlar

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results